PMID- 27746438
OWN - NLM
STAT- MEDLINE
DCOM- 20170201
LR  - 20181202
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 55
IP  - 20
DP  - 2016
TI  - Five Sequential Evaluations of Renal Histology in a Patient with Light Chain 
      Deposition Disease.
PG  - 2993-2999
AB  - A 58-year-old man was referred to our institution for an evaluation of nephrotic 
      range proteinuria. Renal biopsy showed a marked expansion of the mesangial matrix 
      and thickening of glomerular basement membrane (GBM) in periodic acid-silver 
      methenamine (PAM). Immunofluorescence (IF) revealed strong staining for the 
      monoclonal kappa light chain. EM demonstrated massive subendothelial and 
      mesangial dense deposits. As a result, light chain deposition disease (LCDD) was 
      diagnosed. Melphalan and prednisolone (MP) therapy was started, which was 
      continued for 10 years with minimal complications. Serial evaluations of renal 
      histology revealed the resolution of nodular lesions and the glomeruli became 
      nearly normal. MP therapy can therefore be an effective therapeutic option for 
      LCDD if it is continued over the long term.
FAU - Ueno, Toshiharu
AU  - Ueno T
AD  - Nephrology Center, Toranomon Hospital, Japan.
FAU - Kikuchi, Koichi
AU  - Kikuchi K
FAU - Hazue, Ryo
AU  - Hazue R
FAU - Mise, Koki
AU  - Mise K
FAU - Sumida, Keiichi
AU  - Sumida K
FAU - Hayami, Noriko
AU  - Hayami N
FAU - Suwabe, Tatsuya
AU  - Suwabe T
FAU - Hoshino, Junichi
AU  - Hoshino J
FAU - Sawa, Naoki
AU  - Sawa N
FAU - Arizono, Kenji
AU  - Arizono K
FAU - Hara, Shigeko
AU  - Hara S
FAU - Takaichi, Kenmei
AU  - Takaichi K
FAU - Fujii, Takeshi
AU  - Fujii T
FAU - Ohashi, Kenichi
AU  - Ohashi K
FAU - Ubara, Yoshifumi
AU  - Ubara Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20161015
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunoglobulin kappa-Chains)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Glomerular Basement Membrane/*pathology
MH  - Glomerular Mesangium/*pathology
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunoglobulin kappa-Chains/*metabolism
MH  - Male
MH  - Melphalan/therapeutic use
MH  - Middle Aged
MH  - Paraproteinemias/drug therapy/metabolism/*pathology
MH  - Prednisolone/therapeutic use
MH  - Proteinuria/metabolism/*pathology
PMC - PMC5109568
EDAT- 2016/10/18 06:00
MHDA- 2017/02/02 06:00
PMCR- 2016/10/15
CRDT- 2016/10/18 06:00
PHST- 2016/10/18 06:00 [entrez]
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2017/02/02 06:00 [medline]
PHST- 2016/10/15 00:00 [pmc-release]
AID - 10.2169/internalmedicine.55.6213 [doi]
PST - ppublish
SO  - Intern Med. 2016;55(20):2993-2999. doi: 10.2169/internalmedicine.55.6213. Epub 
      2016 Oct 15.